Treatment and Surveillance of Non- Muscle Invasive Bladder Cancer
|
|
- Ross McCoy
- 8 years ago
- Views:
Transcription
1 Treatment and Surveillance of Non- Muscle Invasive Bladder Cancer David Josephson, MD FACS Fellowship Director, Urologic Oncology and Robotic Surgery Program
2 Staging Most important in risk assessment and management Ta confined to mucosa, 70% of non-muscle invasive TCC T1-30% TNM 2002
3 Low grade Ta Rarely progress only 2% Frequently recur 70% need repeat resections Multiplicity Recurrence at first cystoscopy Previous recurrence Tumor size > 3 cm
4 High Grade Ta Low incidence: 2-9% of all non-muscle invasive TCC Mandate repeat TUR to assure accurate staging Intravesical treatment 50% recur 25% progress Potentially lethal 20% may die
5 T1 High incidence of progression 35-48% progress to muscle invasive dz within 3 years when treated by TUR alone Mandate repeat TUR to assure accurate staging and removal of residual tumor burden Frequently understaged or misclassified EORTC 1400 patients: 10% upstaged to T2 on review of path. Lack of muscle in initial specimen 50% have residual dz or are muscle invasive
6 T1 Substaging T1A: invasion superficial to the level of muscularis mucosae (MM) T1B: invasion into MM T1C: invasion through MM but superficial to muscularis propia Worse prognosis with increasing invasion Opponents argue inconsistency, lack of orientation
7 CIS Can increase recurrence rate from 43% to 73% when concomitant Half progress to muscle invasive dz 20% will ultimately die of metastatic dz even with intravesical BCG LIFETIME surveillance especially upper tracts and prostatic urethra
8 Important Factors for Recurrence & Progression Progression and recurrence characteristic Nearly 60-90% with non-muscle invasive dx will recur if treated by TUR alone Factors Grade : better predict progression and mortality Depth: Ta vs T1 Multiplicity Tumor size LVI Recurrence at 3 Months Presence of CIS Sylvester et al Eur Urol 2006
9 RISK GROUP CLASSIFICATION BASED ON STAGE/GRADE Risk Group Recurrence Progression Mortality Low risk: Grade 1 stage Ta Grade 1 stage T1, single tumor 37% 0% 0% Intermediate risk: Grade 1 stage T1, multiple tumors Grade 2 stage Ta Grade 2 stage T1, single tumor 45% 1.8% 0.7% High risk: Grade 2 stage T1, multiple tumors Grade 3 stage Ta Grade 3 stage T1 CIS association 54% 15% 9.5% Overall 48% 7.5% 4.6% Josephson, Expert Rev. Anticancer Ther. 7(4), (2007)
10 Initial TUR or Biopsy preferred histopathological assessment Rule out muscle invasion Laser (Neo/yag) No difference in recurrence Lack of tissue for staging or grading Good for low grade Management
11 Role of Re-resection for T1 TCC Persistent tumor in 27% ta, 37% t1 Even if normal cysto, 17% with residual CA Only 23% of high grade Ta confirmed on review 30% of T1 upstaged if no muscle in initial TUR Critical to further recommendations Schips Urology 59(2), (2002).
12 Intravesical Therapy Not for all patients Traditional indications Multiple and large tumors (> 3 cm) Early recurrence High Grade Ta Any T1 Cis or Lymphovascular invasion Positive cytology after resection of all visible tumor
13 Available agents Chemotherapy: Mitomycin, thiotepa, doxorubicin, epirubicin, Gemcitabine, Valrubicin BCG Immunotherapy Interferon Vitamins A, C, E, selenium Bropiramine
14 Bladder Cancer: Immediate Post-op Chemo Given Peri-Op Single dose Low Morbidity Only for 1 st Tumors Reduces tumor Implants and potentially recurrence in up to 40% Better results in low risk tumors Gudjonsson, Eur Urol 55 (2009), pp ; Ayres, BJU Int, 2010, p 14-7
15 Low Risk Patients: Intravesical Chemotherapy Meta-analysis 4 EORTC Trials 2 MRC Trials Numerous regimens Recurrence 20% risk reduction Progression No impact Pawinski, J Urol 1996, 156; Huncharek, J Clin Epid 2000,
16 BCG vs Chemotherapy BCG superior to thiotepa, epirubicin, adriamycin BCG vs mitomycin mixed results but favor BCG Meta-analysis 1 11 trials 2 year recurrence 38% vs 46% Maintenance had bigger impact 10 yr RFS 2 30% with BCG, no impact of chemo Bohle, J. Urol. 169(1), (2003). Herr, J. Urol. 147, (1992).
17 Intravesical BCG Impacts recurrence & progression 6 wks vs 6 wks + maintenance for 3 years Maintenance regimens differ RFS 5yrs: 41% vs 60% Significant side effects Fever, chills, hematuria Urinary side effects Only 16% for 3 years? If 1/3 dose is equal
18 Carcinoma in Situ (CIS) Up to 50% progress to T2 10% metastasize BCG mainstay of therapy Up to 70% response BCG failure Repeat BCG +/-IFN-a Valrubicin (valstar) 20% response rate Good for poor surgical candidatesd Experimental agents Early Cystectomy Sylvester RJ, Urology 66(6 Suppl. 1), (2005).
19 Intravesical treatment Failures If chemo given, can benefit from BCG If BCG given, considered failure if: higher number of recurrence, increased grade/stage, CIS Muscle invasive disease High grade at both 3 and 6 mo Additional course at 3 mo can provoke response in 50% at 6 mo
20 Surveillance Plan Vigilant follow-up Life long regardless of grade/stage Cystoscopy and Cytology Every 3 months x 2 years Every 6 months x 2 years Annually thereafter Annual CT Urogram to check ureters/kidneys (5% risk) Role of urine based markers uncertain
21 Urine Based Markers FDA APPROVED Stat BTA TRAK Nuclear matrix protein NMP22 FISH :fluorscence in situ hybridization Investigational Hyaluronic acid Cytokeratins BLCA-4
22 Non-Invasive Bladder Cancer Conclusions Two Diseases Low grade Ta: bothersome but treatable T1 and CIS: Can be life threatening Needs Less invasive follow up Better interventions for high risk patients
23 HOPE
Intravesical Therapy for Bladder Cancer
Intravesical Therapy for Bladder Cancer Norm D. Smith, M.D. Chief of Urologic Oncology Department of Urology Northwestern University Feinberg School of Medicine The Problem Bladder cancer Superficial disease
More informationCorporate Medical Policy Urinary Tumor Markers for Bladder Cancer
Corporate Medical Policy Urinary Tumor Markers for Bladder Cancer File Name: Origination: Last CAP Review: Next CAP Review: Last Review: urinary_tumor_markers_for_bladder_cancer 5/2011 11/2015 11/2016
More informationYour bladder cancer diary. WA Cancer and Palliative Care Network
Your bladder cancer diary WA Cancer and Palliative Care Network Patient information and persons to contact Your Name Date of Birth URMN (Patient Hospital Unit Number) Address Phone Mobile GP Name Phone
More informationBLADDER HEALTH. Non-Muscle Invasive Bladder Cancer: A Patient Guide
BLADDER HEALTH Non-Muscle Invasive Bladder Cancer: A Patient Guide What is the Bladder? What is Cancer? The bladder is a balloon-shaped organ in your pelvic* area that stores urine and is made up of four
More informationTreatment of non-muscle-invasive bladder cancer
Treatment of non-muscle-invasive bladder cancer Official reprint from UpToDate www.uptodate.com 2012 UpToDate Treatment of non-muscle-invasive bladder cancer Author Michael A O'Donnell, MD, FACS Disclosures
More informationCurrent Approaches to the Management of Non-Muscle Invasive Bladder Cancer: Comparison of Current Guidelines and Recommendations
european urology supplements 7 (2008) 637 650 available at www.sciencedirect.com journal homepage: www.europeanurology.com Current Approaches to the Management of Non-Muscle Invasive Bladder Cancer: Comparison
More information0022-5347/03/1691-0096/0 Vol. 169, 96 100, January 2003 THE JOURNAL OF UROLOGY. Printed in U.S.A. Copyright 2003 by AMERICAN UROLOGICAL ASSOCIATION
0022-5347/03/1691-0096/0 Vol. 169, 96 100, January 2003 THE JOURNAL OF UROLOGY Printed in U.S.A. Copyright 2003 by AMERICAN UROLOGICAL ASSOCIATION DOI: 10.1097/01.ju.0000035543.69161.58 A RETROSPECTIVE
More informationThese rare variants often act aggressively and may respond differently to therapy than the more common prostate adenocarcinoma.
Prostate Cancer OVERVIEW Prostate cancer is the second most common cancer diagnosed among American men, accounting for nearly 200,000 new cancer cases in the United States each year. Greater than 65% of
More informationPathologic Assessment Of The Breast And Axilla After Preoperative Therapy
Pathologic Assessment Of The Breast And Axilla After Preoperative Therapy W. Fraser Symmans, M.D. Associate Professor of Pathology UT M.D. Anderson Cancer Center Pathologic Complete Response (pcr) Proof
More informationCHEMOTHERAPY FOR ADVANCED UROTHELIAL CANCER OF THE BLADDER. Walter Stadler, MD University of Chicago
CHEMOTHERAPY FOR ADVANCED UROTHELIAL CANCER OF THE BLADDER Walter Stadler, MD University of Chicago Chemotherapy Doctor Terms Drugs used to treat cancer Will attack cancer no matter where it is located
More informationSuperficial Bladder TCC
Superficial Bladder TCC Urology Grand Rounds April 20 2005 John Morrell R4 OBJECTIVES To review the etiology, natural history, and conventional treatments for superficial bladder TCC To review new therapeutic
More informationThomas A. Kollmorgen, M.D. Oregon Urology Institute
Thomas A. Kollmorgen, M.D. Oregon Urology Institute None 240,000 new diagnosis per year, and an estimated 28,100 deaths (2012) 2 nd leading cause of death from cancer in U.S.A. Approximately 1 in 6 men
More informationA practical guide to understanding cancer. Understanding. non-inva sive. bladder. CAncER
A practical guide to understanding cancer Understanding non-inva sive bladder CAncER Contents Contents About this booklet 4 What is cancer? 5 The bladder 7 Risk factors and causes 9 Types of bladder cancer
More informationMetastatic Renal Cell Carcinoma: Staging and Prognosis of Three Separate Cases.
Metastatic Renal Cell Carcinoma: Staging and Prognosis of Three Separate Cases. Abstract This paper describes the staging, imaging, treatment, and prognosis of renal cell carcinoma. Three case studies
More informationTumour Markers. What are Tumour Markers? How Are Tumour Markers Used?
Dr. Anthony C.H. YING What are? Tumour markers are substances that can be found in the body when cancer is present. They are usually found in the blood or urine. They can be products of cancer cells or
More informationOptimal Management of the T1G3 Bladder Cancer
Urol Clin N Am 32 (2005) 133 145 Optimal Management of the T1G3 Bladder Cancer Murugesan Manoharan, MD, FRCS(Eng), FRACS(Urol), Mark S. Soloway, MD* Department of Urology, University of Miami School of
More informationPSA Testing 101. Stanley H. Weiss, MD. Professor, UMDNJ-New Jersey Medical School. Director & PI, Essex County Cancer Coalition. weiss@umdnj.
PSA Testing 101 Stanley H. Weiss, MD Professor, UMDNJ-New Jersey Medical School Director & PI, Essex County Cancer Coalition weiss@umdnj.edu September 23, 2010 Screening: 3 tests for PCa A good screening
More information2008 All rights reserved.
BCAN provides this information as a service. Publication of this information is not intended to take the place of medical care or the advice of your doctor. BCAN strongly suggests consulting your doctor
More informationPost-PET Restaging Cancer Form National Oncologic PET Registry
Post-PET Restaging Cancer Form National Oncologic PET Registry Facility ID #: Registry Case Number: Patient Name: Your patient had a PET scan on: mm/dd/yyyy. The PET scan was done for restaging of (cancer
More informationImplementation Date: April 2015 Clinical Operations
National Imaging Associates, Inc. Clinical guideline PROSTATE CANCER Original Date: March 2011 Page 1 of 5 Radiation Oncology Last Review Date: March 2015 Guideline Number: NIA_CG_124 Last Revised Date:
More informationProstate cancer is the most common cause of death from cancer in men over age 75. Prostate cancer is rarely found in men younger than 40.
A.D.A.M. Medical Encyclopedia. Prostate cancer Cancer - prostate; Biopsy - prostate; Prostate biopsy; Gleason score Last reviewed: October 2, 2013. Prostate cancer is cancer that starts in the prostate
More informationEffective Health Care Program
Comparative Effectiveness Review Number 152 Effective Health Care Program Treatment of Nonmetastatic Muscle-Invasive Bladder Cancer Executive Summary Background Nature and Burden of Nonmetastatic Muscle-Invasive
More information- Slide Seminar - Endocrine pathology in non-endocrine organs. Case 11. Stefano La Rosa, Gioacchino D Ambrosio, Fausto Sessa
- Slide Seminar - Endocrine pathology in non-endocrine organs Case 11 Stefano La Rosa, Gioacchino D Ambrosio, Fausto Sessa Dept. of Pathology, Multimedica, Milan, Italy Dept. of Surgical and Morphological
More informationTherapies for Prostate Cancer and Treatment Selection
Prostatic Diseases Therapies for Prostate Cancer and Treatment Selection JMAJ 47(12): 555 560, 2004 Yoichi ARAI Professor and Chairman, Department of Urology, Tohoku University Graduate School of Medicine
More informationProstate Cancer. Treatments as unique as you are
Prostate Cancer Treatments as unique as you are UCLA Prostate Cancer Program Prostate cancer is the second most common cancer among men. The UCLA Prostate Cancer Program brings together the elements essential
More informationHistorical Basis for Concern
Androgens After : Are We Ready? Mohit Khera, MD, MBA Assistant Professor of Urology Division of Male Reproductive Medicine and Surgery Scott Department of Urology Baylor College of Medicine Historical
More informationPROSTATE CANCER. Get the facts, know your options. Samay Jain, MD, Assistant Professor,The University of Toledo Chief, Division of Urologic Oncology
PROSTATE CANCER Get the facts, know your options Samay Jain, MD, Assistant Professor,The University of Toledo Chief, Division of Urologic Oncology i What is the Prostate? Unfortunately, you have prostate
More informationDoes my patient need more therapy after prostate cancer surgery?
Does my patient need more therapy after prostate cancer surgery? Contact the GenomeDx Patient Care Team at: 1.888.792.1601 (toll-free) or e-mail: client.service@genomedx.com Prostate Cancer Classifier
More informationCarcinoma of the vagina is a relatively uncommon disease, affecting only about 2,000 women in
EVERYONE S GUIDE FOR CANCER THERAPY Malin Dollinger, MD, Ernest H. Rosenbaum, MD, Margaret Tempero, MD, and Sean Mulvihill, MD 4 th Edition, 2001 Vagina Jeffrey L. Stern, MD Carcinoma of the vagina is
More informationAdiuwantowe i neoadiuwantowe leczenie chorych na zaawansowanego raka żołądka
Adiuwantowe i neoadiuwantowe leczenie chorych na zaawansowanego raka żołądka Neoadiuvant and adiuvant therapy for advanced gastric cancer Franco Roviello, IT Neoadjuvant and adjuvant therapy for advanced
More informationStomach (Gastric) Cancer. Prof. M K Mahajan ACDT & RC Bathinda
Stomach (Gastric) Cancer Prof. M K Mahajan ACDT & RC Bathinda Gastric Cancer Role of Radiation Layers of the Stomach Mucosa Submucosa Muscularis Serosa Stomach and Regional Lymph Nodes Stomach and Regional
More informationPSA Screening for Prostate Cancer Information for Care Providers
All men should know they are having a PSA test and be informed of the implications prior to testing. This booklet was created to help primary care providers offer men information about the risks and benefits
More informationTransurethral Resection of Bladder Tumour (T.U.R.B.T)
Transurethral Resection of Bladder Tumour (T.U.R.B.T) Patient Information Introduction This booklet has been written to help you understand the surgery you are about to undergo. It will give you information
More informationHER2 Status: What is the Difference Between Breast and Gastric Cancer?
Ask the Experts HER2 Status: What is the Difference Between Breast and Gastric Cancer? Bharat Jasani MBChB, PhD, FRCPath Marco Novelli MBChB, PhD, FRCPath Josef Rüschoff, MD Robert Y. Osamura, MD, FIAC
More informationHEALTH NEWS PROSTATE CANCER THE PROSTATE
HEALTH NEWS PROSTATE CANCER THE PROSTATE Prostate comes from the Greek meaning to stand in front of ; this is very different than prostrate which means to lie down flat. The prostate is a walnut-sized
More informationBeyond the PSA: Genomic Testing in Localized Prostate Cancer
Beyond the PSA: Genomic Testing in Localized Prostate Cancer Kelvin A. Moses, MD, PhD Vanderbilt University Medical Center Wednesday, December 2, 2015 5:00 p.m. ET/2:00 p.m. PT About ZERO ZERO s mission
More informationGUIDELINES FOR THE MANAGEMENT OF LUNG CANCER
GUIDELINES FOR THE MANAGEMENT OF LUNG CANCER BY Ali Shamseddine, MD (Coordinator); as04@aub.edu.lb Fady Geara, MD Bassem Shabb, MD Ghassan Jamaleddine, MD CLINICAL PRACTICE GUIDELINES FOR THE TREATMENT
More informationThe Whipple Operation for Pancreatic Cancer: Optimism vs. Reality. Franklin Wright UCHSC Department of Surgery Grand Rounds September 11, 2006
The Whipple Operation for Pancreatic Cancer: Optimism vs. Reality Franklin Wright UCHSC Department of Surgery Grand Rounds September 11, 2006 Overview Pancreatic ductal adenocarcinoma Pancreaticoduodenectomy
More informationIntegrating Chemotherapy and Liver Surgery for the Management of Colorectal Metastases
I Congresso de Oncologia D Or July 5-6, 2013 Integrating Chemotherapy and Liver Surgery for the Management of Colorectal Metastases Michael A. Choti, MD, MBA, FACS Department of Surgery Johns Hopkins University
More informationRotation Specific Goals & Objectives: University Health Network-Princess Margaret Hospital/ Sunnybrook Breast/Melanoma
Rotation Specific Goals & Objectives: University Health Network-Princess Margaret Hospital/ Sunnybrook Breast/Melanoma Medical Expert: Breast Rotation Specific Competencies/Objectives 1.0 Medical History
More informationBridging Techniques. What s between EMR and Traditional Surgery? Elisabeth C. McLemore, MD, FACS, FASCRS
Bridging Techniques What s between EMR and Traditional Surgery? Elisabeth C. McLemore, MD, FACS, FASCRS Associate Professor of Surgery Assistant Program Director, General Surgery Residency Disclosures
More information1. What is the prostate-specific antigen (PSA) test?
1. What is the prostate-specific antigen (PSA) test? Prostate-specific antigen (PSA) is a protein produced by the cells of the prostate gland. The PSA test measures the level of PSA in the blood. The doctor
More informationChallenges in gastric, appendiceal and rectal NETs Leuven, 29.11.2014
Challenges in gastric, appendiceal and rectal NETs Leuven, 29.11.2014 Prof. Dr. Chris Verslype, Leuven Prof. Dr. Aurel Perren, Bern Menue Challenges: 1. Gastric NET 2. Appendiceal NET 3. Rectal NET SEER,
More informationBladder Cancer What is bladder cancer?
Bladder Cancer What is bladder cancer? Bladder cancer begins when cells in the urinary bladder start to grow uncontrollably. As more cancer cells develop, they can form a tumor and spread to other areas
More informationCancer of the Cardia/GE Junction: Surgical Options
Cancer of the Cardia/GE Junction: Surgical Options Michael A Smith, MD Associate Chief Thoracic Surgery Center for Thoracic Disease St Joseph s Hospital and Medical Center Phoenix, AZ Michael Smith, MD
More informationBLADDER CANCER GLOSSARY OF TERMS
BLADDER CANCER GLOSSARY OF TERMS Abdomen: The part of the body that contains the pancreas, stomach, intestines, kidneys, urinary bladder, liver, gallbladder, and other organs. Anesthesia: Loss of feeling
More informationTargeted Therapy What the Surgeon Needs to Know
Targeted Therapy What the Surgeon Needs to Know AATS Focus in Thoracic Surgery 2014 David R. Jones, M.D. Professor & Chief, Thoracic Surgery Memorial Sloan Kettering Cancer Center I have no disclosures
More informationPrincipal Investigator: Valerie W. Rusch, MD, FACS, Chief, Thoracic Surgery Memorial Sloan-Kettering Cancer Center
Protocol 1101-1088 Phase I study of intra-pleural administration of GL-ONC1 in patients with malignant pleural effusion: primary, metastases and mesothelioma Principal Investigator: Valerie W. Rusch, MD,
More informationRadiation Therapy for Prostate Cancer: Treatment options and future directions
Radiation Therapy for Prostate Cancer: Treatment options and future directions David Weksberg, M.D., Ph.D. PinnacleHealth Cancer Institute September 12, 2015 Radiation Therapy for Prostate Cancer: Treatment
More informationThe PSA Controversy: Defining It, Discussing It, and Coping With It
The PSA Controversy: Defining It, Discussing It, and Coping With It 11 TH ANNUAL SYMPOSIUM ON MEN S HEALTH June 12, 2013 The PSA Controversy Defining It, Discussing It and Coping With It As of May 2012,
More informationSaturation Biopsy for Diagnosis and Staging of Prostate Cancer. Original Policy Date
MP 7.01.101 Saturation Biopsy for Diagnosis and Staging of Prostate Cancer Medical Policy Section Surgery Issue 12/2013 Original Policy Date 12/2013 Last Review Status/Date /12/2013 Return to Medical Policy
More informationAvastin in breast cancer: Summary of clinical data
Avastin in breast cancer: Summary of clinical data Worldwide, over one million people are diagnosed with breast cancer every year 1. It is the most frequently diagnosed cancer in women 1,2, and the leading
More informationRobert Bristow MD PhD FRCPC
Robert Bristow MD PhD FRCPC Clinician-Scientist and Professor, Radiation Oncology and Medical Biophysics, University of Toronto and Ontario Cancer Institute/ (UHN) Head, PMH-CFCRI Prostate Cancer Research
More informationSquamous Cell Carcinoma of Anal Canal Treatment Guidelines
May 2009 Squamous Cell Carcinoma of Anal Canal Treatment Guidelines Presented at Cancer Committee: August 6, 2009 By Shelly Smits, RHIT, CCS, CTR Conclusions by Ian Thompson, MD Data Source: Cancer registry
More informationProtein kinase C alpha expression and resistance to neo-adjuvant gemcitabine-containing chemotherapy in non-small cell lung cancer
Protein kinase C alpha expression and resistance to neo-adjuvant gemcitabine-containing chemotherapy in non-small cell lung cancer Dan Vogl Lay Abstract Early stage non-small cell lung cancer can be cured
More informationProstate Cancer 2014
Prostate Cancer 2014 Eric A. Klein, M.D. Chairman Glickman Urological and Kidney Institute Professor of Surgery Cleveland Clinic Lerner College of Medicine Incidence rates, US Men Mortality Rates, US Men
More informationChapter 13. The hospital-based cancer registry
Chapter 13. The hospital-based cancer registry J.L. Young California Tumor Registry, 1812 14th Street, Suite 200, Sacramento, CA 95814, USA Introduction The purposes of a hospital-based cancer registry
More informationGuidelines for Management of Renal Cancer
Guidelines for Management of Renal Cancer Date Approved by Network Governance July 2012 Date for Review July 2015 Changes Between Versions 2 and 3 Section 5 updated bullets 5.3 and 5.4 Section 6 updated
More informationKidney Cancer OVERVIEW
Kidney Cancer OVERVIEW Kidney cancer is the third most common genitourinary cancer in adults. There are approximately 54,000 new cancer cases each year in the United States, and the incidence of kidney
More informationSMALL CELL LUNG CANCER
Protocol for Planning and Treatment The process to be followed in the management of: SMALL CELL LUNG CANCER Patient information given at each stage following agreed information pathway 1. DIAGNOSIS New
More informationUpdate on Prostate Cancer: Screening, Diagnosis, and Treatment Making Sense of the Noise and Directions Forward
Update on Prostate Cancer: Screening, Diagnosis, and Treatment Making Sense of the Noise and Directions Forward 33 rd Annual Internal Medicine Update December 5, 2015 Ryan C. Hedgepeth, MD, MS Chief of
More informationAnalysis of Prostate Cancer at Easter Connecticut Health Network Using Cancer Registry Data
The 2014 Cancer Program Annual Public Reporting of Outcomes/Annual Site Analysis Statistical Data from 2013 More than 70 percent of all newly diagnosed cancer patients are treated in the more than 1,500
More informationA bladder cancer glossary
A bladder cancer glossary We ve put together a list of the medical terms you might hear people use when they talk about bladder cancer. Abdomen The middle part of your body that contains your stomach,
More informationMesothelioma. Malignant Pleural Mesothelioma
Mesothelioma William G. Richards, PhD Brigham and Women s Hospital Malignant Pleural Mesothelioma 2,000-3,000 cases per year (USA) Increasing incidence Asbestos (50-80%, decreasing) 30-40 year latency
More informationClinical Trials: Muscle-Invasive Bladder Cancer. Wednesday May 18 th, 2016. Part II: Current Areas of Research
Clinical Trials: Muscle-Invasive Bladder Cancer Wednesday May 18 th, 2016 Part II: Current Areas of Research Presented by Seth P. Lerner, MD is a Professor of Neurology at Baylor College of Medicine. He
More informationEMR Can anyone do this?
EMR Can anyone do this? Norio Fukami, MD University of Colorado Piecemeal resection? 1 Endoscopic mucosal resection (EMR) and Endoscopic submucosal dissection (ESD) Endoscopic removal of premalignant or
More informationUpdate on thyroid cancer surveillance and management of recurrent disease. Minimally invasive thyroid surgery
Update on thyroid cancer surveillance and management of recurrent disease Minimally invasive thyroid surgery July 2006 Michael W. Yeh, MD Program Director, Endocrine Surgery Assistant Professor, David
More informationCombined Harvard Urologic Oncology Fellowship Program
Combined Harvard Urologic Oncology Fellowship Program 1 Goal: Department of Urology To reduce the disease burden for patients with urologic issues by improving: Clinical Care Teaching Research 2 History
More informationBladder Cancer Overview
Bladder Cancer Overview This overview is based on the more detailed information in our document, Bladder Cancer: Detailed Guide. What is bladder cancer? Cancer starts when cells in the body begin to grow
More informationA918: Prostate: adenocarcinoma
A918: Prostate: adenocarcinoma General facts of prostate cancer The prostate is about the size of a walnut. It is just below the bladder and in front of the rectum. The tube that carries urine (the urethra)
More informationبسم هللا الرحمن الرحيم
بسم هللا الرحمن الرحيم Updates in Mesothelioma By Samieh Amer, MD Professor of Cardiothoracic Surgery Faculty of Medicine, Cairo University History Wagner and his colleagues (1960) 33 cases of mesothelioma
More informationCONTEMPORARY MANAGEMENT OF RENAL ANGIOMYOLIPOMA
CONTEMPORARY MANAGEMENT OF RENAL ANGIOMYOLIPOMA Stephen A. Boorjian, MD Professor of Urology Vice Chair of Research Director, Urologic Oncology Fellowship Department of Urology Mayo Clinic, Rochester,
More informationHow To Treat A Uterine Sarcoma
EVERYONE S GUIDE FOR CANCER THERAPY Malin Dollinger, MD, Ernest H. Rosenbaum, MD, Margaret Tempero, MD, and Sean Mulvihill, MD 4 th Edition 2001 Uterus: Uterine Sarcomas Jeffrey L. Stern, MD Uterine sarcomas
More informationRecurrence, Progression, and Follow-Up in Non Muscle-Invasive Bladder Cancer
EUROPEAN UROLOGY SUPPLEMENTS 8 (2009) 556 562 available at www.sciencedirect.com journal homepage: www.europeanurology.com Recurrence, Progression, and Follow-Up in Non Muscle-Invasive Bladder Cancer Antoine
More informationChing-Yao Yang, Yu-Wen Tien
Ching-Yao Yang, Yu-Wen Tien Division of General Surgery, Department of Surgery, National Taiwan University Hospital Oct-30-2010 Pancreatic NET have poorer prognosis when presence of liver metastases at
More informationPSA screening: Controversies and Guidelines
PSA screening: Controversies and Guidelines John Phillips, MD, FACS Department of Urology Urology Center of Westchester New York Medical College Historical PerspecGve Cancer of the prostate, although rare,
More informationSecondary Cancer and Relapse Rates Following Radical Prostatectomy for Prostate-Confined Cancer
Copyright E 2007 Journal of Insurance Medicine J Insur Med 2007;39:242 250 MORTALITY Secondary Cancer and Relapse Rates Following Radical Prostatectomy for Prostate-Confined Cancer David Wesley, MD; Hugh
More informationNICE guideline Published: 25 February 2015 nice.org.uk/guidance/ng2
Bladder cancer: diagnosis and management NICE guideline Published: 25 February 2015 nice.org.uk/guidance/ng2 NICE 2015. All rights reserved. Your responsibility The recommendations in this guideline represent
More informationColumbia University Mesothelioma Applied Research Foundation - 2009 - www.curemeso.org. Mesothelioma Center www.mesocenter.org
Columbia University Mesothelioma Center www.mesocenter.org Multimodal clinical trials, treatment (surgery, radiation, chemotherapy) Peritoneal mesothelioma program Immunotherapy translational, experimental
More informationFAQ About Prostate Cancer Treatment and SpaceOAR System
FAQ About Prostate Cancer Treatment and SpaceOAR System P. 4 Prostate Cancer Background SpaceOAR Frequently Asked Questions (FAQ) 1. What is prostate cancer? The vast majority of prostate cancers develop
More informationA Woman s Guide to Prostate Cancer Treatment
A Woman s Guide to Prostate Cancer Treatment Supporting the man in your life Providing prostate cancer support and resources for women and families WOMEN AGAINST PROSTATE CANCER A Woman s Guide to Prostate
More informationEarly Prostate Cancer: Questions and Answers. Key Points
CANCER FACTS N a t i o n a l C a n c e r I n s t i t u t e N a t i o n a l I n s t i t u t e s o f H e a l t h D e p a r t m e n t o f H e a l t h a n d H u m a n S e r v i c e s Early Prostate Cancer:
More informationProstate Cancer In-Depth
Prostate Cancer In-Depth Introduction Prostate cancer is the most common visceral malignancy among American men. In the year 2003, there are expected to be 220,000 new cases and nearly 29,000 deaths in
More informationHow To Know If You Should Get A Brachytherapy Or Radioactive Seed Implantation
MEDICAL POLICY SUBJECT: BRACHYTHERAPY OR PAGE: 1 OF: 5 If the member's subscriber contract excludes coverage for a specific service it is not covered under that contract. In such cases, medical policy
More informationAvastin in breast cancer: Summary of clinical data
Avastin in breast cancer: Summary of clinical data Worldwide, over one million people are diagnosed with breast cancer every year 1. It is the most frequently diagnosed cancer in women 1,2, and the leading
More informationLung Cancer Treatment Guidelines
Updated June 2014 Derived and updated by consensus of members of the Providence Thoracic Oncology Program with the aid of evidence-based National Comprehensive Cancer Network (NCCN) national guidelines,
More informationUnderstanding ductal carcinoma in situ (DCIS) and deciding about treatment
Understanding ductal carcinoma in situ (DCIS) and deciding about treatment Developed by National Breast and Ovarian Cancer Centre Funded by the Australian Government Department of Health and Ageing Understanding
More informationA912: Kidney, Renal cell carcinoma
A912: Kidney, Renal cell carcinoma General facts of kidney cancer Renal cell carcinoma, a form of kidney cancer that involves cancerous changes in the cells of the renal tubule, is the most common type
More informationHow TARGIT Intra-operative Radiotherapy can help Older Patients with Breast cancer
How TARGIT Intra-operative Radiotherapy can help Older Patients with Breast cancer Jeffrey S Tobias, Jayant S Vaidya, Frederik Wenz and Michael Baum, University College Hospital, London, UK - on behalf
More informationManagement of Peritoneal Metastases (PM) from colorectal cancers: New Perspectives. Dominique ELIAS
Management of Peritoneal Metastases (PM) from colorectal cancers: New Perspectives Dominique ELIAS Declaration of interest BOARDS Congress and teaching 0 Merck 0 Ipsen Novartis Sanofi Trials The peritoneum
More informationUnderstanding Metastatic Disease
Supported by an unrestricted educational grant from Pfizer Understanding Metastatic Disease Metastatic disease or metastases are phrases that mean the same as Secondary cancer. This means that the cancer
More informationPROSTATE CANCER 101 WHAT IS PROSTATE CANCER?
PROSTATE CANCER 101 WHAT IS PROSTATE CANCER? Prostate cancer is cancer that begins in the prostate. The prostate is a walnut-shaped gland in the male reproductive system located below the bladder and in
More informationwww.downstatesurgery.org
Male Breast Cancer Rabih Nemr MD Kings County Hospital August 2008 ACGME Core Competencies 1 Patient t Care Medical Knowledge 2 g 3 4 Practice Based Learning/Improvement Interpersonal Communication Skills
More informationSeton Medical Center Hepatocellular Carcinoma Patterns of Care Study Rate of Treatment with Chemoembolization 2007 2012 N = 50
General Data Seton Medical Center Hepatocellular Carcinoma Patterns of Care Study Rate of Treatment with Chemoembolization 2007 2012 N = 50 The vast majority of the patients in this study were diagnosed
More informationCurrent Status and Perspectives of Radiation Therapy for Breast Cancer
Breast Cancer Current Status and Perspectives of Radiation Therapy for Breast Cancer JMAJ 45(10): 434 439, 2002 Masahiro HIRAOKA, Masaki KOKUBO, Chikako YAMAMOTO and Michihide MITSUMORI Department of Therapeutic
More informationReport series: General cancer information
Fighting cancer with information Report series: General cancer information Eastern Cancer Registration and Information Centre ECRIC report series: General cancer information Cancer is a general term for
More informationda Vinci Prostatectomy Information Guide (Robotically-Assisted Radical Prostatectomy)
da Vinci Prostatectomy Information Guide (Robotically-Assisted Radical Prostatectomy) Prostate Cancer Overview Prostate cancer is a disease in which malignant (cancer) cells form in the tissues of the
More informationPancreatic Cancer: FDA Approved Treatments and Clinical Trials
Pancreatic Cancer: FDA Approved Treatments and Clinical Trials Vincent J Picozzi MD MMM Virginia Mason Medical Center Seattle WA 1 Pancreatic cancer is the hardest cancer of all to treat 2 Pancreatic cancer:
More informationInnovations in Kidney Cancer
Innovations in Kidney Cancer Guest Expert: Harriet, MD Associate Professor of Medical Oncology Edward, MD Assistant Professor of Surgical Urology www.wnpr.org www.yalecancercenter.org Welcome to Yale Cancer
More informationOpen the Flood Gates Urinary Obstruction and Kidney Stones. Dr. Jeffrey Rosenberg Dr. Emilio Lastarria Dr. Richard Kasulke
Open the Flood Gates Urinary Obstruction and Kidney Stones Dr. Jeffrey Rosenberg Dr. Emilio Lastarria Dr. Richard Kasulke Nephrology vs. Urology Nephrologist a physician who has been trained in the diagnosis
More information